Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration has approved Revatio (sildenafil) Injection, an intravenous formulation of Revatio. The company said that Revatio is the only FDA-approved phosphodiesterase-5 or PDE5 inhibitor available in both tablet and intravenous formulations.
Revatio is indicated for the treatment of adult patients with pulmonary arterial hypertension (WHO Group I) to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when Revatio was added to background epoprostenol therapy. The efficacy of Revatio has not been adequately evaluated in patients taking bosentan concurrently. Revatio Injection is for the continued treatment of patients with pulmonary arterial hypertension who are currently prescribed Revatio Tablets but who are temporarily unable to take oral medication, the company said.
Pfizer noted that the most common side effects of Revatio are nosebleeds, headache, upset stomach, flushing, and trouble sleeping. At doses more than the approved 20 milligrams 3 times a day, some side effects increased. These included flushing, loose stools, muscle pain, and visual disturbances.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.